Industry Insights

71. What Your Company Can Learn From The Technology Shift Occurring In The Life Sciences Industry 3/28/2014

    The pharmaceutical and life sciences industry has a lot riding on proficient document management. The faster and more efficiently these companies can get a drug or device to market, the more successful and profitable their business. That’s why it’s somewhat surprising that the industry has been a bit of a laggard in document management. By Kevin Potts, NextDocs

72. Supply Chain Risk Where You Least Expect It — Good Supply Practices For The Life Sciences 8/7/2017

    The medtech, pharma, and biotech industries are concerned about their inability to consistently ensure the supply of incoming materials. This article offers recommendations for good supply practices - assembled by a team of FDA officials and industry professionals - that reduces the risk to finished product quality, patient safety, and business success.

73. The Need For Digital Networks To Support Cell And Gene Therapies 12/30/2019

    Cell and gene therapies have a level of complexity from a supply chain perspective that needs new approaches, including a high level of information sharing and integration. This topic was covered from different perspectives at two recent conferences.

74. Rapid Growth In Life Science Sector Constrains Capital Projects Supply Chain 2/14/2018

    Demand increase for process equipment coupled with shortage of construction labor will require proactive engagement with vendors/contractors and greater due diligence to ensure predictable results.

75. Turning Off The Engine Of Cancer 8/19/2013

    New medical therapies are turning off the engine of cancer inside the human body and making progress toward eliminating most cancers over the next few decades. If South Carolina is willing to recognize its existing centers of medical excellence and fund serious research in this field, it will see companies and clinics quickly spring up to support and apply these advances.
    
    Despite billions of dollars spent over decades on cancer research, death rates for many of the most common cancers have remained stubbornly close to the rates of half a century ago. It often has seemed that the more we’ve discovered about the cancers that plague us, the more we’ve found them to be simply too complex to defeat.

76. Biosimilar Discounting & Contracting: What Can The U.S. Learn From Europe? 3/14/2018

    In this two-part series, we will consider multiple facets of the EU’s influence on biosimilar adoption. Part 1 will focus on payer coverage of biosimilars and the role of discounting and contracting. Part 2 will highlight the effects of the NOR-SWITCH trial results and how the EU’s view of biosimilars as therapeutic alternatives, rather than generics, has influenced U.S. policy.

77. A Patient-Centric Approach To Increase Recruitment And Retention In Clinical Trials 4/16/2019

    Good recruitment and retention is critical to the success of clinical trials. Get it right, and a trial will likely achieve its primary objective; get it wrong, and the time, effort, expense, and any patient participation is likely wasted. This article discusses how a new national approach to involving patients and the public in the U.K. is helping life sciences companies get it right the first time.

78. The Importance Of Inventory Management: Do You Know Where Your Samples Are? 6/12/2019

    With the exciting advances in research and drug development, the importance of sample management has never been higher. If you have ever experienced sample management mishaps, we ask: Do you know where your samples are? In this article, we’ll explore some of the common causes of inventory mismanagement and best practices to guard against sample loss and near misses.

79. 10 Steps To Develop A Sustainable Training Program For Pharma Operations 10/16/2017

    Development of a successful and sustainable training program requires appropriate policies for guidance, as well as an infrastructure to ensure proper development, deployment, and administration.

80. Determining Significant Vs. Nonsignificant Risk In Medical Devices 5/24/2018

    Knowing how to classify your device as either SR or NSR is not a clearly defined task. There are implications for each decision made as you proceed through development, and the burden is on you to understand and to provide what the FDA will require.